Drugs that contain Pralsetinib

1. List of Gavreto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10030005 GENENTECH INC Inhibitors of RET
Nov, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 GENENTECH INC RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 4, 2025
Orphan Drug Exclusivity (ODE) Sep 4, 2027

NCE-1 date: 2024-09-04

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy

Dosage: CAPSULE;ORAL

More Information on Dosage

GAVRETO family patents

19

United States

6

Japan

3

China

3

Israel

3

European Union

2

Singapore

2

Brazil

2

Korea, Republic of

2

Canada

2

Chile

2

Australia

1

Russia

1

Costa Rica

1

Philippines

1

Mexico

1

Argentina

1

Morocco

1

Peru

1

Taiwan, Province of China

1

Hong Kong

1

EA

1

South Africa

1

Saudi Arabia

1

Ecuador

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic